Emerging Treatment Options for the Management of Moderate to Severe Psoriasis

Jerry Bagel, MD, MS, provides an overview of potential challenges in managing plaque psoriasis and assess to biologics utilized in plaque psoriasis.

Jerry Bagel, MD, MS, discuss new targets, treatment goals, and utilizing shared decision making when treating patients with plaque psoriasis.

An expert dermatologist details the effect of the COVID-19 pandemic and other comorbidities on treatment selection for plaque psoriasis.

Dr Jerry Bagel describes the unmet needs of plaque psoriasis management.

An overview of the novel selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib for the management of plaque psoriasis.

Jerry Bagel, MD, MS, explains clinical trial data on the investigational anti-IL17A/F monoclonal antibody bimekizumab.

Dr Jerry Bagel looks to the future of moderate-to-severe plaque psoriasis management.